The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.
An analysis of electronic medical records for more than 45,000 people found that COVID-19 infection was significantly associated with the development of high blood pressure, according to new research published today in Hypertension, an American Heart Association journal.
A new University of California, Irvine-led study uncovers how a protein, APOBEC3B, could protect cells against many different types of RNA viruses like respiratory syncytial virus (RSV), SARS-CoV2, influenza virus, poliovirus and measles, helping to prevent disease.
A new vaccine developed by the University of Georgia might be the first clinically approved immunization to safeguard against invasive fungal infections, which are becoming more common as antifungal drug resistance grows.
According to a recent study of information from the Veterans Affairs Million Veteran Program, there are genetic correlations between COVID-19 severity and specific medical disorders that are established risk factors for severe COVID-19.
A new type of cell that resides deep within human lungs and may play a key role in human lung diseases has been discovered by researchers at the Perelman School of Medicine at the University of Pennsylvania.
Researchers at Baylor College of Medicine, Yale University and other institutions have identified previously unrecognized changes in gene expression and cellular interactions in distinct cell populations in chronic obstructive pulmonary disease (COPD).
In 2019, the WHO positioned chronic obstructive pulmonary disease (COPD) third in the global ranking of causes of death.
Scientists from the National Institutes of Health recently found a therapy that targets host cells instead of bacterial cells in treating bacterial pneumonia.
Rutgers researchers have discovered that people with asthma and chronic obstructive pulmonary disease have a protein in their lungs that leaks a small molecule into their bloodstream that restricts their breathing instead of relaxing their airways.
Mucus is an essential protective layer of gel-like liquid composed largely of proteins called mucins throughout our airways.
Are prematurely aged or overworked stem cells a significant factor in chronic lung disease? Findings of a study just released in STEM CELLS Translational Medicine (SCTM) say this is likely so.
Increased air pollution in recent years has not only contributed to deteriorating environmental conditions in cities across the globe.
Researchers propose that similar to pouring water atop a wellhead prior to pumping, the airway cells of patients suffering from chronic lung diseases are “primed” for infection by the COVID-19 virus.
Researchers have demonstrated that gene-edited cellular treatments can effectively treat cardiovascular and pulmonary disorders.
Research shows that inhibiting necroptosis, a form of cell death, could be a novel therapeutic approach for treating chronic obstructive pulmonary disease (COPD), an inflammatory lung condition, also known as emphysema, that makes it difficult to breathe.
(Boston)--Chronic Obstructive Pulmonary Disease (COPD) is a disease caused by cigarette smoking that reduces lung function and causes difficulty breathing.
Patients who have preexisting respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD) and live in areas with high levels of air pollution have a greater chance of hospitalization if they contract COVID-19, says a University of Cincinnati researcher.
Researchers at the Perelman School of Medicine at the University of Pennsylvania have produced a detailed molecular atlas of lung development, which is expected to be a fundamental reference in future studies of mammalian biology and of new treatments for diseases, such as COVID-19, that affect the lungs.
New cutting-edge research undertaken at the University of Leicester could revolutionize the way new drugs are developed and the way patients are cared for, through a pioneering new approach using virtual clinical trials.
New findings indicate that melatonin could be a potential treatment option for COVID-19.